This review seeks to highlight the enormous potential of targeted nanoparticles for molecular imaging applications. Being the closest point-of-contact, circulating nanoparticles can gain direct access to targetable molecular markers of disease that appear on the endothelium. Further, nanoparticles are ideally suitable to vascular targeting due to geometrically enhanced multivalent attachment on the vascular target. This natural synergy between nanoparticles, vascular targeting and molecular imaging can provide new avenues for diagnosis and prognosis of disease with quantitative precision. In addition to the obvious applications of targeting molecular signatures of vascular diseases (e.g., atherosclerosis), deep-tissue diseases often manifest themselves by continuously altering and remodeling their neighboring blood vessels (e.g., cancer). Thus, the remodeled endothelium provides a wide range of targets for nanoparticles and molecular imaging. To demonstrate the potential of molecular imaging, we present a variety of nanoparticles designed for molecular imaging of cancer or atherosclerosis using different imaging modalities.
Introduction
Historically, nanoparticles have been engineered predominantly for applications that require them to target tissues beyond the vascular endothelium. In this review, we refer to this strategy as 'deep-tissue targeting'. This comes with no surprise considering that the first success story of nanoparticles was based on exploiting the intratumoral accumulation of particles via passive means through the leaky vasculature of tumors due to the enhanced permeability and retention (EPR) effect [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . However, an increasing number of publications indicate that the impact of the EPR effect in deep-tissue targeting is inconsistent, resulting in a patchy, near-perivascular accumulation of nanoparticles in tumors [14] [15] [16] . To further increase specificity, targeting ligands have also been employed to direct nanoparticles to upregulated receptors on cells at sites of disease. Precise targeting of cells in diseased tissue (deep-tissue targeting) requires that the nanoparticle has to successfully overcome a series of biobarriers including evasion of the immune system (intravascular transport), extravasation across the endothelium (transvascular transport), navigation through the extracellular space (interstitial transport) and finally meaningful interactions with the intended cell-surface receptors on the target cells. Thus, it is nearly impossible to identify a single design for a nanoparticle that takes under consideration each and every biobarrier. This typically leads to nanoparticles capable of successfully tackling only a subset of the biobarriers, compromising the overall effectiveness of targeting.
Here, we review the rationale and applications of targeting nanoparticles to the endothelium for molecular imaging of biomarkers associated with disease. Besides blood components and plasma proteins, the vascular endothelium is the closest point-of-contact for circulating nanoparticles. By having direct access to the vascular bed, one can envision that nanoparticles can continuously scavenge the endothelium for biomarkers of disease. Thus, considering elimination of two challenging biobarriers (i.e., transvascular and interstitial transport), vascular targeting may be more effective than deep-tissue targeting in many occasions.
While conventional agents of small molecular weight are rapidly distributed within diseased and healthy tissues in a non-specific manner due to the enhanced diffusion of small molecules, we suggest that nanoparticles are highly suitable for vascular targeting due to enhanced targeting avidity as a result of geometrically enhanced multivalent attachment to the vascular target. In fact, the size and the multivalent avidity, due to formation of multiple receptor-ligand bonds, make nanoparticles ideal for targeting of vascular-associated pathologies. However, even if the targeting scheme appears to be simplified than deeptissue targeting scenarios, one still has to consider the enormous availability of different nanoparticle designs in terms of size, shape and composition, which directly govern the particle's ability to target a specific vascular site and generate detectable signals using various imaging modalities. Further, depending on the exact diagnostic requirements of a disease, the design of the nanoparticle has to be mindful of the clinical deployment and radiological imaging. For example, a clinical problem may significantly benefit from the high sensitivity of positron emission tomography (PET) compared to the higher resolution or soft tissue information provided by magnetic resonance imaging (MRI) or X-ray computed tomography (CT). While these considerations may appear overwhelming at first, one of the principle features of nanotechnology is its engineerable nature, which provides multiple degrees of freedom facilitating the fabrication of nanoparticles with the distinct properties required by a specific application.
This review also seeks to illustrate that the objective of molecular imaging of diseased endothelium using nanoparticles is not just to take 'pretty pictures' but rather provide new and useful information to physicians and impact their decision-making process. To demonstrate the potential of molecular imaging, we will present applications on two representative diseases, cancer and atherosclerosis. Obviously there are applications of molecular imaging and targeted nanoparticles on many diseases, we selected cancer and atherosclerosis because the field has significantly focused on them. We will first briefly introduce the pathobiology of the two diseases and their characteristics that are related to vascular targeting and molecular imaging (e.g., targetable upregulated biomarkers). For more details about the pathogenesis and development of the two diseases, we guide the reader to comprehensive reviews. In the proceeding sections, we will then discuss design criteria of nanoparticles that dictate their vascular targeting effectiveness. After this discussion, we will review a variety of nanoparticles designed for molecular imaging of cancer or atherosclerosis using nuclear imaging, optical imaging, CT, MRI, ultrasound and multimodal imaging.
Disease pathobiology and its influence on the endothelium

Cancer
Tumor growth often occurs by the successful hijacking of an existing blood supply and the local angiogenesis that follows de novo to mediate nourishment of the fast proliferating tumor mass [17] . Largely due to its rapid growth, the tumor microenvironment is strikingly different from healthy tissue [18] [19] [20] [21] [22] . The vasculature feeding a tumor is often convoluted and disordered, and blood flow is significantly slowed, transiently stagnant, or even reversed (Fig. 1 ) [22] [23] [24] . There are also a large number of vascular shunts that shuttle blood directly from an arteriole to a venule. Early studies showed that the tumor vasculature is inherently 'leaky', where the tight cell-cell junctions between endothelial cells that normally serve to maintain tissue integrity are compromised. In a developing tumor, endothelial cells of angiogenic vessels are often further apart (up to 400-600 nm between cells) [25] . This finding in the early 1980′s, termed the enhanced permeability and retention (EPR) effect, jump-started a burgeoning field where a large spectrum of untargeted imaging and therapeutic agents were delivered via the circulation in the hopes that a significant proportion of the dose would be passively retained by the tumor mass [1, [26] [27] [28] [29] [30] [31] . Certainly there has been some success with EPR delivery of nanoparticles for imaging and therapy. However, this strategy also has serious shortcomings, namely achieving tumor-specific targeting within short timescales, achieving efficient tumor penetration necessary for therapeutic efficacy, and targeting small tumors such as metastases that may not be well vascularized. Further and importantly, there is a high interstitial pressure barrier within a tumor mass that may be difficult for nanoparticles to overcome to penetrate deeper tissue. As such, in the decades following, efforts to drive efficient, active vascular targeting of nano-agents have gained much attention. Compared to achieving the deep-tissue penetration necessary to target the tumor cells themselves, efforts to preferentially target the tumor-associated vascular endothelium are arguably simpler and intuitively more promising in their increased homing efficacy. Besides applications in molecular imaging, from a therapeutic perspective, methods to mechanically or chemically trigger release of drug cargoes from nanoparticles homing to the tumorassociated vascular bed can serve to deliver therapeutic payloads to deeper tissue as necessary, if vascular delivery is not adequate. From a discovery perspective, vascular-targeted nano-platforms have provided much information regarding tumor progression and pathogenesis. Notably, however, the presence of an EPR effect, no matter how small, can also complicate nanoparticle targeting efforts for molecular imaging of the tumor-associated endothelium. Given that the goal of molecular imaging is to glean quantifiable information regarding the tumor vasculature, in cases where the EPR effect is strong, even vascular-targeted nanoparticles may readily traverse the endothelial layer for retention within the tumor mass, thereby giving a 'false-positive' reading. To address this shortcoming, many vascular targeting platforms quantitatively compare targeted particle homing to untargeted particle homing. If necessary, targeted microbubbles can be employed since, by virtue of their larger size (N 1 μm), they cannot extravasate into the tumor mass [32] .
Contrary to small molecules that are cleared relatively quickly from blood circulation, the prolonged blood residence time of PEGylated nanoparticles generates sufficient 'interfering' signal in the lumen of blood vessels to prohibit discrimination of signal from blood vessel walls (i.e., target site) with a high degree of confidence. Thus, imaging must be delayed for days after injection of a long-circulating nanoparticle to allow the agent to clear from the bloodstream. In addition, which leads to a new 'interfering' signal from EPR-driven deposition of the nanoparticle. To accurately differentiate vascular targeting from signals in the blood pool or deep-tissue, investigators have optimized and identified a low dose of nanoparticles agents that generated significantly detectable signal on the tumor-associated vascular bed and insignificant background "noise" due to the blood circulation of the nanoparticle or its non-specific uptake in various organs (e.g., liver, spleen) [85, 88, 87] .
In addition to the 'leakiness' of the tumor vasculature, there are a host of other microenvironmental factors that drives tumor-specific endothelial cell changes that can be readily exploited for designing targeted nanoparticles. The tumor niche, particularly the necrotic center farthest away from the blood supply, is extremely hypoxic and cells switch to anaerobic glycolysis, resulting in lactate build-up and local acidity. Further, rapid metabolic demands leave the tumor tissue often glucose-/nutrient-starved and there are high levels of oxidative stress on the tumor and associated cells. There is also considerable lymphogenesis where the tumor develops its own lymphatic supply that funnels in tumor-promoting immune cells that drive proliferation and eventual metastasis. Collectively, these processes have a fundamental impact on the tumor-associated endothelium, which divides rapidly and plays a central role in angiogenesis, in marked contrast to healthy endothelial tissue that is often described as quiescent [18, 20, 21] .
Quite conveniently, endothelial cells are also uniquely transcriptionally rich compared to many other cell types. In response to aberrant tumor-induced environmental stimuli, vascular endothelial cells express strikingly different surface markers, often referred to as a tumorspecific 'molecular signature', the complete elucidation of which will prove invaluable for understanding and treating cancer [18, 20] . Many high-throughput strategies have been employed to isolate unique tumor-associated endothelial surface biomarkers to exploit these molecules as vascular targets. Microarray analysis, serial analysis of gene expression (SAGE) analysis, and in vivo phage-displayed peptide libraries are all methods that have provided key insight. Taken together, key families of endothelial surface molecules have been isolated, many of which are involved in tumor cell migration and metastasis. These include classes of integrins (specifically, α v β 3 and α v β 5 ), the family of tumor endothelial markers (TEMs, TEM8 especially), cell adhesion molecules (CAMs), vascular/epidermal growth factors and their receptors (V/EGF and V/EGFR), selectins, cell surface nucleolin, and fibrinfibronectin complexes [18, 20, 33] . Markers such as VEGF have been exploited as therapeutic anti-angiogenesis targets in the clinic, with the antibody bevacizumab being a key example [20, 34, 35] .
In addition to relying solely on the 'molecular signature' of the tumor-associated vascular endothelium, nanoparticle targeting strategies may benefit greatly from co-delivery of vascular mediators that have been well-established as powerful effectors of the diseased endothelium. For example, co-delivery of potent vasodilators such as bradykinin, angiotensin converting enzyme inhibitors (ACE inhibitors), nitric oxide, prostacyclins, tumor necrosis factor α (TNFα), and nitroglycerin may enhance tumor-specific delivery of targeted nanoparticles [3, 4, 6, 8, 9, 28, 31, [36] [37] [38] . This strategy has significant relevance in both diagnostic/imaging and therapeutic applications.
Currently, the choice of clinical imaging modality varies by tumor type and stage of disease. For example, CT and MRI are used widely in scenarios where tumor structure is readily discernible as in the cases of brain or liver cancer, while radionuclide-based methods that can detect tumor cell function with high sensitivity are used to detect smaller tumors as in the case of lymphomas. Across the spectrum of modalities, however, current imaging methods have limitations such as inadequate soft tissue contrast, sensitivity, and resolution particularly at the critical early stage of tumor development when accurate diagnoses and immediate treatment can have tremendous value. As a result, there is a clear need for the development of effective imaging agents, and targeting the tumor vasculature using nanoparticle technology has high relevance in this setting.
Cardiovascular disease
We focus here specifically on atherosclerosis since it is perhaps the most predominant cardiovascular condition and has benefitted greatly from vascular imaging. As such, much effort has been placed on driving the field forward with the development of nanoparticles as molecular imaging agents of the atherosclerotic endothelium, for both diagnostic Reproduced with permission from reference [22] . and therapeutic purposes. Aberrant changes in cholesterol transport are central for disease pathogenesis. Cholesterol is moved throughout the body via two types of lipoprotein carriers, high-density lipoproteins (HDLs) and low-density lipoproteins (LDLs), commonly referred to as 'good' and 'bad' cholesterol, respectively. High levels of HDLs are inversely related to cardiac events, as their main functionality is to remove cholesterol from the bloodstream and shuttle it to the liver for excretion. LDLs, the main transporters of cholesterol, are responsible for transporting cholesterol to cells for metabolic functions. Unlike high HDL levels, high levels of LDLs are directly responsible for plaque buildup in the arterial intima, resulting in increased risk of stroke and heart failure. At this stage, this condition is called atherosclerosis [39] .
Certain portions of the vasculature are more susceptible to the morphological changes that enable plaque formation. These changes include increased adhesiveness and permeability, and typically occur at vascular sites where blood flow is disturbed, such as at arterial branches, bifurcations, and areas with high vascular curvature. Changes in flow at these sites cause decreased shear stress and increased turbulence, which alters gene expression in the associated endothelium [40] . In addition to flow disturbances, other factors such as smoking, diabetes, hypercholesterolemia, hypertension, and infection all have effects in inducing endothelial cell changes [41] . Endothelial dysfunction is the first step in atherogenesis. The diseased endothelium's permeability makes it highly susceptible to LDL influxes. High plasma concentrations of LDLs can lead to lumen penetration and accumulation in the intima. Here, LDLs are progressively oxidized to become toxic modified-LDLs; the increased toxicity in the arterial lumen consequently promotes an inflammatory response. Monocytes and lymphocytes emigrate from the blood into the intima, drawn in by the oxidized LDLs and their byproducts.
Just prior to this inflammatory immune cell transmigration, endothelial cells upregulate expression of P-and E-selectins, which are involved in the rolling and tethering of monocytes onto the vascular wall. Further endothelial upregulation of molecules of the CAM family (i.e., ICAMs and VCAM-1) increase the adhesiveness of the endothelium, promoting the arrest of the inflammatory cells on the vascular surface. Upon docking, upregulated PECAM-1 assists the monocytes in migrating from the vessel wall to the intima in a process called transmigration [42] . Notably, in contrast to other members of the CAM family, PECAM-1 (CD31) is found at junctions between cells in both healthy and diseased tissue [42, 43] . As such, even though it may not serve adequately as a lone target, because of its high expression, it may prove highly effective as a homing agent on dual-or multi-targeted nanoparticles that also display other targets. Integrins are also a key component in the arrest and transmigration of monocytes to the diseased tissue.
Once embedded in the intima, antigen-presenting monocytederived macrophages are responsible for scavenging and engulfing the modified-LDLs. In order to continue macrophage recruitment and survival, the macrophages already in the intima will secrete cytokines such as macrophage colony-stimulating factor. Upon continual scavenging, the lipid-laden macrophages develop into foam cells that eventually undergo necrosis after lipid saturation [44] . The necrotic cells eventually release their contents into the lesion site as they die and form a necrotic core, otherwise known as plaque. As a whole, this inflammatory response is chronic since plaques will continue to build in the arterial wall as long as there is persistence of modified-LDLs in the intima. As the plaque enlarges, the smooth muscle surrounding the artery compensates for plaque growth by expanding itself outward without affecting the lumen lining; this is known as 'remodeling' [40] . Early atherosclerosis is non-occlusive as this characteristic is due to arterial remodeling.
Critically, atherosclerosis is difficult to detect using conventional imaging, such as angiography, due to the lack of vessel abnormalities at this stage. As the disease progresses, the atherosclerotic lesion will protrude into the vessel leading to thrombosis. Angiography during this stage will be able to detect lesions, as there is clear vessel deformation that is easily discernible. As the necrotic core continues to expand into the lumen, a fibrous cap overlying the necrotic core will start to thin, making the plaque susceptible to rupture, which may lead to stroke and/or myocardial infarction. Fibrous cap thinning is also caused by flow disruption in the vasculature [45] . Notably, as also discussed previously with respect to targeting tumors, co-delivery of targeted nanoparticles with potent vasodilators such as nitroglycerin may reduce local blood pressure and reverse turbulent flow patterns and may, as a result, have an effect in combatting and treatment plaque formation [8] . Notably, the smaller vessels that make up the vasa vasorum are more susceptible to plaque formation compared to larger vessels, likely because they undergo neovascularization as part of their function in feeding the larger arteries and veins [46] . While not fully established, the endothelial 'leakiness' that can result as a part of this vessel remodeling may aid in the collection of macrophages and inflammation mediators that drive atherosclerotic plaque formation [46, 47] .
Currently, angiography and small molecule imaging modalities are key techniques used in clinical settings for atherosclerosis imaging [48] . Fluorodeoxyglucose (FDG)-PET imaging is also used to visualize and measure macrophage activity [49, 50] . While these techniques are efficient and effective in detecting late-stage atherosclerosis, they are unsuccessful in imaging early-stage atherosclerosis or identifying late-stage vulnerable plaques before they rupture [51] . As such, nanoparticle-based imaging of atherosclerotic lesions has been of increasing interest in recent years since molecular imaging will be of tremendous value to effective interventions. To this end, some efforts have focused on macrophage imaging, but because rodent and rabbit models have significantly higher macrophage counts than humans, in vivo studies have often not been accurate at correctly depicting human disease. Here, we focus on vascular molecular targeting and imaging of the atherosclerotic endothelium via over-expressed endothelial cell markers using prevalent imaging modalities [52, 53] . Given that the process of atherosclerotic plaque formation is similar between humans and current animal models with respect to changes in the vascular endothelium, to our knowledge to date, there are no significant discrepancies in clinical translation of results from animal models of the disease.
Considerations of blood flow
Characteristics of healthy vasculature
Blood flow and changes in flow patterns are key contributing factors in the development of cancer and atherosclerosis [54] . Understanding blood flow is also centrally important to the design and engineering of an optimally targeted vascular nanoparticle. The human vascular system has three primary types of blood vessels: arteries, for distribution of oxygen and metabolites; veins, for collection of metabolic waste and carbon dioxide; and capillaries, the smallest of all vessels, which are exchange points for blood nutrients and tissue metabolites. Vascular endothelial cells, which line all of the vessels in the circulatory system, are at the interface between the blood and the vessel wall. They have a number of functions, including filtration and transport, hemostasis, and neutrophil recruitment. They also play a role in vessel regulation; mechanoreceptors enable sensing of shear stress due to blood flow, which allows vessels to adapt to flow by changing diameter and wall thickness. Blood flow within a vessel is directly proportional to pressure gradients and inversely proportional to vascular resistance. Resistance, in turn, is a function of friction between the endothelial cell lining and the flowing blood. It is inversely proportional to vessel radius to the fourth power such that the larger the vessel, the smaller the resistance, and the faster the flow. Notably, small changes in vessel radius as due to a growing tumor or atherosclerotic plaque can lead to sizeable changes in vascular resistance. Further, blood flow is known to streamline when moving through long smooth vessels. Continuous flow in this manner becomes laminar and is characterized by a parabolic flow profile. Due to their extremely high cross sectional area, capillaries such as those in the center of tumor masses have very slow blood velocities, which enables high interaction of the blood content (i.e., carrying nanoparticles) with the vascular endothelium [54] .
Flow changes during tumor angiogenesis
As a tumor develops and undergoes an 'angiogenic switch', an otherwise controlled system of vessels and flow patterns becomes distinctly chaotic [17, 21, 55, 56] . Tumor vasculature is highly dependent on tumor type (including differences between primary tumors and metastases), location, and growth rate. Tumor blood vessel dimensions are different from the host vasculature. They are highly irregular and notoriously leaky, with open endothelial junctions, some perforated endothelium, and often either an abnormally thick or conversely a very thin basement membrane. In dramatic contrast to healthy vessels, blood flow within tumors does not necessarily follow the laminar flow pattern, and there is no dependence on vessel diameter. Flow rates may be orders of magnitude lower than in healthy vasculature, and in some cases may even reverse direction. The variability in flow rates may be due in part to the increased resistance in tumor blood vessels. Another factor that can play a role is the opposing forces that govern the high permeability of the tumor vasculature versus the interstitial fluid pressure. Collectively as a result of these vascular flow changes, tumor vessels are often susceptible to blood clot formation [5, 57, 58] . Finally, rapidly proliferating cancer cells generate a solid stress on tissue, which may contribute to flow effects (Fig. 2) [59] .
Blood flow rates are heterogeneous throughout tumor tissue, which in general is divided into regions based on vascularization and permeability [21, 60] . The central-most regions are avascular and necrotic, with low flow rates, while the surrounding regions contain a stabilized microcirculatory system that typically has highly variable flow rates. In many cases, increases in systemic blood pressure has been shown to increase blood flow to tumors in comparison to healthy organs, but these flow increases are notably not homogenous throughout the entire tumor mass [5, 7, 61] . This heterogeneity can complicate efforts to disperse therapeutic agents throughout the entire tumor mass. While it may be possible to deliver agents to the well vascularized, highly permeable region at the periphery of a tumor, these molecules have to rely on diffusion to reach the center. This diffusion process is slow, and in addition, these molecules may be carried away from the central regions by convection of interstitial fluid. This physiological makeup is a key driving force for developing targeted nanoparticles that home to the tumor vascular face in lieu of particles that must penetrate deeper into the tumor tissue [2] .
Flow changes during atherosclerotic plaque development
Blood vessels are subject to a number of hemodynamic forces. Cumulative changes in these forces play a central role in atherosclerotic plaque formation. Endothelial cells in particular are sensitive to flow patterns and fluid shear stress. In straight vessels where flow is laminar, wall shear stress is high and directed along the vessel surface. Changes in shear stress play a critical role in vascular homeostasis [62] . When blood flow transitions from laminar, parabolic flow to turbulent flow, blood flows across the vessel (and no longer along it) and eddy currents are formed. Eddy currents significantly increase the resistance to blood flow. Turbulent flow is a direct function of blood velocity and an inverse function of viscosity. Turbulent flow also occurs when there are changes in the structure of a vessel, such as a sharp turn, a rough surface, or an obstruction (Fig. 3 ).
There are a number of conditions that lead to disturbed flow in the vascular system. These include natural disturbances due to branch points and curved arteries, and disturbances created through surgical interventions, such as stent placement. While some conditions are lasting, others, such as flow changes during organ transplantation, may be temporary. Disturbances in flow contribute to a number of clinical disorders, including atherosclerosis and arterial aneurysms [63] . Disturbed flow also results in lower shear stress and creation of shear stress gradients and is known to upregulate endothelial cell genes and proteins that promote atherogenesis. For example, shear stress-induced production of endothelial nitric oxide synthase (eNOS) in the vascular endothelium also serves to increase local blood flow, which in turn can exacerbate the formation of eddy currents and plaque development [36, 37] . As a result, disturbed flow can lead to localization of atherosclerotic lesions. The growing plaque may develop a positive feedback loop, continuing to disrupt blood flow to feed its growth, which may potentially lead to a vessel obstruction. Interestingly, the rate of atherosclerosis progression can vary even between segments of the same vessel, because it is dependent on highly local differences in flow disturbance. In advanced lesions, weakened artery walls can lead to pressure-induced aneurysms [62, 63] .
Nanoparticle design
Nanoparticles versus small molecules, antibodies, and aptamers
Design considerations for optimal vascular targeting agents involve evaluation of the properties of several major classes of molecules [18, 26] . Small organic molecules can be synthesized and functionalized easily, penetrate rapidly and deeply within tissues, and can be structurally altered to control their pharmacokinetics. The chief disadvantage here, however, is achieving high-affinity binding, which has serious implications in targeting and imaging accuracy. In comparison, monoclonal antibodies have perhaps the highest target binding affinities (micromolar to picomolar dissociation constants) among ligand classes. They can be raised to bind to nearly every target and, when applications require smaller ligand sizes, antibodies can be decoupled into smaller component fragments that retain similar functional binding capability. Peptide ligands, often only~3-12 amino acids in length, are advantageous because of their relatively small size (even smaller than antibody fragments). They typically have dissociation constants in the micromolar range, but further improvements in affinity can rarely be achieved because of limited high-affinity binding peptide sequences available for some antigens. Aptamers can be easily prepared with dissociation constants in the micromolar to nanomolar range. The challenge here, however, is the necessity for thorough testing to ascertain properties that govern stability in vivo [18] .
Compared to these classes of molecules, the use of nanoparticles significantly broadens the scope for 'engineerability' of unique agents tailored specifically for imaging of the diseased endothelium [20, 21, 60, 64] . Nanoparticle technology spans a vast gamut of potential material choices (or combinations of materials). These include polymeric materials that can constructed to be biodegradable, metallic particles, lipidbased particles or liposomes, nucleic acid-based particles, and proteinrich materials, all of which have unique benefits and drawbacks that can be tuned in an application-dependent manner [65] [66] [67] [68] . Methods of chemistry can also be adapted to synthesize particles of various sizes and shapes, including the more traditional spheres and rods as well as nano-flowers, -cubes, -worms, -chains, -discs, -stars, and even nano-snowflakes [66, 69] . This tuning of nanoparticle structure can play a critical role in targeting efficiency, which is important in vascular targeting applications where particles have to maneuver through the blood circulation. Furthermore and very importantly, particles can often be functionalized with targeting moieties and agents that confer important biological properties such as water-solubility, endowed with imaging capabilities that may not be intrinsic, and, most often, encapsulated with drug payloads that must be delivered for therapeutic efficacy. Notably, while the FDA has approved some relatively inert nanoparticle formulations such as certain liposomes for use in clinical trials, approval for the majority of particles that are currently at the pre-clinical stage will require comprehensive toxicity analysis for both short-and long-term side effects [70] .
4.2. Nanoparticle size, shape, and surface composition as central design criteria
Vascular targeting requires that particles are able to tumble out of the general blood circulation, marginate along vessel walls, and attach with relatively high affinity to their cognate targets. The endothelial landscape and the flow and shear considerations involved can vary significantly. For example, particles that are built to target a wellvascularized primary tumor may benefit from the sluggish blood flow within the irregular tumor capillaries and accurate targeting of the entire tumor vasculature may not be much of a challenge. By contrast, particles constructed to target metastases or even early micrometastases that grow intimately along the endothelium of larger vessels, have to overcome considerably larger flow velocities and shear stresses in order to home successfully. Size, shape, and surface composition are key governing factors that define efficient particle delivery and function. These criteria vary by nanoparticle application and here, we discuss considerations specifically important for the design of particles for vascular targeting in terms of their influences on particle pharmacokinetics, margination, and avidity of binding.
Particle size plays a central role in their clearance, which has important implications for toxicity related to long-term retention. Particles b 10 nm in size are cleared rapidly via the renal filtration system, while larger particles are cleared by the liver and spleen [71] [72] [73] [74] . Further, it has been shown that targeting of nanoparticles in different microenvironments varies dramatically (anywhere from one to three orders of magnitude) depending on the particle size. In general, smaller particles are able to marginate along vessel walls more avidly than larger particles that tend to move along with the general circulation [69] . Specifically in the tumor-associated vasculature, particle size appears to play a role in targeting efficiency. FMT imaging studies using vascular EGFR-targeted liposomes of smaller (30 nm) and larger (100 nm) sizes in mice with primary breast tumors showed that targeting of 30-nm liposomes was significant compared to untargeted 30-nm liposomes, untargeted 100-nm liposomes, and even targeted 100-nm liposomes when blood flow rate is slow as in the core of the tumor mass [61] . However, when flow rate increases, there appeared to be no difference in deposition between targeted and untargeted liposomes, but 100-nm liposomes accumulated much more significantly at the tumor and associated vasculature than 30-nm liposomes. In regards to binding avidity, larger particles enable more multivalent decoration with targeting moieties, and, as such, favor greater binding compared to smaller particles [75] [76] [77] .
Compared to spherical particles, asymmetric oblong particles such as nanorods and discs appear to have important shape-based advantages with respect to circulation and binding avidity (Fig. 4) . While spherical particles can be cleared by macrophages of the mononuclear phagocytic system (MPS, also known as the reticuloendothelial system) of the liver and spleen, rod-shaped particles are endocytosed to a lesser degree [78] [79] [80] . Because of lower clearance rates, rod-like particles may circulate longer. Further, because oblong particles are subjected to torque forces within blood flow, they have a tendency to tumble out of the general circulation and 'scavenge' along vessel walls [81] [82] [83] [84] [85] . This concept has been uniquely illustrated by studies using iron-oxide nanochains, which are constructed from 3 to 4 nanospheres covalently linked together [85] [86] [87] [88] [89] [90] [91] . Nanochains were targeted to vascular Reproduced with permission from reference [63] .
endothelial and tumor cell-associated markers and, in studies involving imaging and treatment of tumors that are notoriously difficult to target such as breast tumor micrometastases and invasive brain tumors, nanochains were able to marginate to tumor sites within only 1-3 h of injection significantly more than individual iron oxide spheres or liposomes. Finally, in terms of binding avidity, oblong particles may offer greater multivalency than their spherical counterparts, but they can also offer higher avidity since ligands are arranged on a planar surface and available in greater numbers in comparison to spherical particles where curvature limits the number of ligands available for binding at a given instance [92, 93] .
Nanoparticle surface chemistry dictates the first point-of-contact a particle has with its environment and governs the efficiency with which it binds to its cognate target receptor. Vascular targeting requires that particles are soluble in the blood and can remain in circulation for at least several hours post-injection [94] . To this end, particles are often coated with water-soluble polymers such as polyethylene glycol (PEG). For accurate targeting, particles must be functionalized with a critical mass number of surface ligands [94] [95] [96] . Several studies have explored targeting effects with more than one type of ligands under the premise of achieving higher deposition at target sites [96, 97] . This strategy of 'multi-targeting' is especially relevant when nanoparticles exploit endothelial surface markers that vary by disease stage. Using more than one target offers a greater chance of targeting a tumor growing between stages that can otherwise escape detection and improves overall targeting accuracy of the tumor as a whole.
Targeting strategies
So far, we have discussed how the design of a nanoparticle dictates its biochemical and biophysical interactions with the target site. First, the biophysical interactions of nanoparticles with the vascular bed can be tweaked by changing their size and shape. Second, due to their size, nanoparticles can be decorated with a large number of ligands, which significantly augments the biochemical interactions with the complex tumor microenvironment. Furthermore, presentation of ligands (e.g., length of PEG) and ligand density can be controlled on the nanoparticle's surface. The number of nanoparticles targeting a cellsurface receptor is maximized at an optimal number of ligands per particle. Once this point is crossed, the ligands in excess unnecessarily consume receptors resulting in early receptor saturation and diminishing the targeting likelihood of forthcoming particles.
In particular, the vascular bed upregulates specific biomarkers that often reflect the state of the diseased tissue behind the endothelium. To increase targeting accuracy, various ligands and targeting strategies have been used to image vascular biomarkers of disease that are different from healthy tissues. Obviously, the selected targets should be minimally expressed on normal resting blood vessels. As discussed in Section 2.2, in the case of atherosclerosis, typical targets include the CAM family (i.e., ICAMs and VCAM-1), integrins, selectins and other adhesive molecules involved in the recruitment of leukocytes in inflammation. Notably, a subset of these biomarkers are also targetable in cancerous tissues, since they are key players in the process of angiogenesis and metastasis (Section 2.1). Importantly, the early spread of metastasis to distant organs lacks the typical angiogenic activity seen in many types of solid tumors. Even though typical angiogenic markers are not available for targeting in the case of metastasis, many of the adhesive molecules found in inflammation are present (e.g., integrins, selectins). Considering that the early metastatic spread of cancer cells involves extravascular metastases (i.e., cancer cells residing inside the lumen of blood vessels), the cancer cells carry a continuously evolving phenotype including varying overexpression of cell surface receptors (e.g., folate, EGF, HER2, CD30, integrin receptors).
Another important consideration is that atherosclerosis and cancer should not be approached as monoliths. They are both highly dynamic diseases with cells evolving and changing over time and space, including the expression of targetable cell-surface receptors. Thus, it is important to capture this dynamic microenvironment, which is missed by a traditional single-ligand strategy. This is another major advantage of nanoparticles over single molecule targeting probes. Presentation of different types of ligands can be easily controlled on the surface of nanoparticles in terms of ligand density and ratio among different ligand types. Such multi-targeting system is 'adaptable' to the dynamic nature of disease by considering the spatiotemporal changes of targetable receptors within the same patient, leading to effective targeting of different locations or regions of the disease that predominantly express different targetable receptors at any given time.
In the next section, we review different nanoparticle platforms and their applications on molecular imaging of cancer or atherosclerosis using different imaging modalities.
Molecular imaging applications
Particles for nuclear imaging
Nuclear-based methods for imaging such as single-photon emission computed tomography (SPECT) and PET are among the first techniques developed for vascular targeting applications. Since radionuclides can be detected with very high sensitivity (in the pM range) without issues with deep tissue penetration and signal can be easily quantified, nuclear imaging has become the standard modality for molecular imaging in particular. Its chief limitation, however, is its relatively low spatial resolution at~5 mm. As a result, compared to the number of nanoparticlebased targeting methods that solely rely on nuclear imaging, there are a large number of nanoparticle platforms developed using multimodal imaging (see Section 5.6). In these cases, multimodal studies rely on nuclear methods for sensitivity and other modalities for high spatial resolution. In Section 5.7, we summarize all the key features of the different imaging modalities and provide an overall perspective on selecting the appropriate nanoparticle for molecular imaging applications in terms of regulatory approvals and clinical adaptation.
In the case of cancer and molecular imaging of angiogenesis in particular, a large number of studies have involved radiolabeled antibodies that bind with high affinity to well-established biomarkers such as VEGF/ VEGFR with both SPECT and PET [98] Tc [42, [102] [103] [104] have been used as radiotracers attached to VEGF/VEGFR for SPECT imaging, while 124 I has been used for PET [75, 76] . Additionally, 111 In and 89 Zr have been attached to bevacizumab for SPECT and PET studies, respectively [106] . In the particle landscape, 64 Cu-labeled, α v β 3 integrin-tagged single-walled nanotubes (SWNTs) were also used for angiogenesis imaging via SPECT [107] . 99 Tc-labeled liposomes co-labeled with ligands for both P-selectin and α v β 3 integrins were used to effectively corroborate by SPECT imaging short-term early targeting at vascular sites of breast metastasis that was initially imaged by optical imaging (fluorescence molecular tomography or FMT) [97] . Similarly, gold nanoparticles targeted to vascular endothelial/tumor cell α v β 3 integrins were co-labeled with 99 Tc and SPECT imaging was used to quantify the minimal particle dose that reached lung metastases within only 1 h of injection (Fig. 5) . Notably here, because of the extraordinary sensitivity of SPECT imaging, measurements could be made using a very small dose of gold nanoparticle [91] . Other studies using gold particles targeted to vascular endothelial/tumor cell α v β 3 integrins and co-labeled with 125 I showed by SPECT/CT imaging that effective targeting occurred rapidly within 10 min post-injection at brain tumor sites and that particles were endocytosed for longer-term retention [108] . Similarly, PET imaging has also been used for vascular targeting of the tumor-associated endothelium. CD105-targeted gold nanoshells [109] and integrin-targeted mesoporous silica nanoparticles [110] , both co-labeled with 64 Cu, have been used in PET studies of the vascular endothelium.
By contrast, advances in nuclear imaging with regards to the use of nanoparticles for vascular targeting of the diseased endothelium in atherosclerosis have been limited. SPECT studies using Tc-labeled single domain antibody fragments with nanomolar affinities to human and mouse VCAM-1 (cyclic antibody VCAM1-5, cAbVCAM1-5) was used to monitor expression levels following anti-atherogenic treatments. VCAM-1 expression appeared to be directly correlated to plaque size [111] . 
Particles for optical imaging
Optical imaging methods, particularly those that are fluorescencebased, are extensively used in pre-clinical studies for their costeffectiveness, high sensitivity, absence of ionizing radiation and related toxicity, and ability for imaging in real-time. There is, however, a notable difference in achievable spatial resolution between microscopybased optical methods (e.g., confocal imaging) that can readily discern even sub-cellular structures~100 nm apart and small animal optical imaging where resolution is limited to a few millimeters [22] . Significantly, this discrepancy has important implications for accurate molecular imaging since resolution is an important parameter. Further, while confocal imaging is combined with multi-photon imaging to achieve deep tissue penetration and to minimize autofluorescence in pre-clinical settings, clinical imaging methods are often limited to the use of nearinfrared (NIR) dyes because only these wavelengths can penetrate tissue for depth imaging.
In the case of cancer and molecular studies of the developing tumorassociated endothelium in bone marrow-homing acute lymphoblastic leukemia (ALL) cells, in vivo immunofluorescence confocal/multiphoton microscopy using intravenously injected antibodies targeted to overexpressed endothelial selectins and CAMs have been used extensively for dynamic imaging purposes [112] . Because fluorescent probes can be readily attached to antibodies that inherently have very high binding affinities, this method of imaging was developed early and represents a simple and highly sensitive method in studies of vascular targeting of diseased endothelium. In comparison, fluorescent nanoparticles (i.e., liposomes [113] , silica [113] , polymersomes [113] , rare-earth nanocrystals [114] ) are used to achieve longer retention at target sites and associated vasculature, for multimodal imaging studies, and to simultaneously carry drugs for delivery. For example, fluorescent cationic liposomes~50 nm in diameter have shown a significant increase in affinity for angiogenic endothelial cells in pancreatic islet tumors compared to neutral and anionic liposomes as quantified by confocal imaging analysis . Engineered fluorescent viruses have also been used for vascular targeting studies. Filamentous bacteriophages constructed to express targeting peptides and used to isolate tumor vascular targets, have been shown by confocal microscopy to bind with high affinity to upregulated α v β 3 and α v β 5 integrins in the pancreatic islet tumor vasculature via RGD-4C and RGD [118] [119] [120] . Inert, biocompatible, and multivalent plant viruses such as the cowpea mosaic virus (CPMV) have also shown to accumulate preferentially in the periphery of the vascular lumen and have been used in confocal and intravital imaging studies of neo-angiogenesis of even the smallest of capillaries [121] . Further, in situ three-dimensional fluorescence cryogenic imaging (3D cryo-imaging [122] [123] [124] ) that allows for whole-body imaging has also been used for imaging/detection of small metastatic tumors (b0.5 mm) and associated stroma/endothelium following intravenous injection of fluorescent peptides that target the upregulated fibrinfibronectin complexes [125] .
As discussed earlier, clinical imaging modalities have largely relied on the use of NIR dyes to achieve deep tissue penetration. Fluorescence molecular tomography (FMT) studies have shown that NIR dye-tagged liposomes functionalized with two endothelial/tumor cell targets (specifically, for P-selectin and α v β 3 integrins) have significantly greater targeting efficiency in models of triple-negative breast cancer compared to liposomes functionalized with only a single target [97] . Similar FMT studies with NIR-tagged EGFR-targeted liposomes have shown liposome size-dependent deposition within primary mammary tumors as a function of local blood flow measured in parallel by micro-CT [61] . Quantum dots (QDs) have shown much potential for clinical imaging because of their high signal intensity but their utility for medical imaging/diagnosis has been severely limited by their toxicity [126] [127] [128] [129] [130] [131] [132] [133] . Recent efforts to synthesize QDs that are biocompatible, NIR-fluorescent, ultra-small (5-nm), stable in vivo, and cleared via the renal circulation, have however been promising [134] . Dendroncoated InP/ZnS QDs targeted to α v β 3 integrins in both ovarian tumor cells and associated vasculature resulted in high signal retention lasting longer than 24 h compared to untargeted QDs [134] . Not surprisingly, NIR-tagged RGD-labeled quantum dots (QDs) have been used to visualize tumor-associated vascular α ν β 3 integrins with intravital imaging [135, 136] . Finally, besides fluorescence-based techniques, optical imaging methods that rely on the strong surface plasmon resonance properties of metallic particles such as gold spheres [137] [138] [139] , rods [140, 141] , and nanocages [142] [143] [144] targeted to tumor-associated vascular EGFR have also been developed.
In the case of vascular targeting of atherosclerosis and in vivo optical imaging, NIR dye-tagged magneto-optical particles have been used to target VCAM-1 and monitor expression changes in real-time using intravital imaging [145] [146] [147] . Similarly, plaque-associated VCAM-1 has been targeted using ultrasmall SPIO particles and imaged with combined optical, SECARS, and electron microscopy [148] .
Particles for CT
X-ray based techniques such as CT, mammography, and tomosynthesis are among the oldest and most widely used clinical imaging modalities today. CT-based imaging is often the first method of choice for detection of cancer and cardiovascular disease. It is widely available in clinical settings and has key advantages including low cost, quick scan times, very high spatial resolution, and precise signal quantification. As early as in the 80s, lipid-based contrast agents were developed for tumor imaging. For instance, Lipiodol is often used to exclude benign from malignant lesions in the liver and kidneys [149] [150] [151] . There is, however, an inherent risk of exposure to harmful ionizing radiation, which is increasingly minimized with newer generation scanners. Still, the chief limitation of CT-based techniques particularly using nanoparticles for molecular imaging is the low-contrast sensitivity of X-rays (in the mM range) that limits soft tissue discernment [64] . As a result, detection currently relies on increased expression of target biomarkers where contrast agent can accumulate at the high concentrations requisite to overcome the detection threshold. However, this necessity is a significant obstacle in detecting early stages of vascular disease where biomarker expression is often sparse. Iodine has been the most widely used X-ray contrast agent in clinical CT imaging. For instance, iodine has been encapsulated within liposomal nanoparticles and used to characterize the tumor vasculature studies in mice bearing mammary tumors using micro-CT imaging (Fig. 6) [61] . There is, however, much effort invested in developing CT contrast agents that have higher X-ray attenuation and better contrast. High atomic weight metallic nanomaterials such as gold, bismuth, and rare-earth elements have been studied for this purpose. Notably, because many of these metallic particles are non-degradable, toxicity and clearance analysis is an important consideration in developing novel CT nanoparticle agents for clinical translation.
In the case of cancer, gold nanoparticles (both spheres and rods) have been readily functionalized with vascular endothelial (EGFR [152] ) and tumor cell (HER2 [150, 151] , PSMA [155] , folate receptor [156] , UM-A9 [157] ) targets for molecular CT imaging, where studies have shown marked differences in retention in tumor-associated areas compared to untargeted particles. Specifically, EGFR-targeted gold particles enabled effective CT visualization of the tumor-associated vasculature in mouse head and neck carcinoma where tumors are a comparatively small~4-5 mm [152] . Similarly, bismuth-sulfide particles attached to LyP-1 targeting the tumor-associated lymphatic endothelium and (to a lesser extent) tumor cells themselves allowed CT-based imaging of breast tumors even 24 h after injection [158] . Further, upconversion nanoparticles, which are rare-earth/lanthanide-doped (Gd-, Yb-, Lu-doped) particles, are naturally luminescent and can convert lower energy radiation to higher energy radiation.
In the case of atherosclerosis, coronary CT angiography is used widely for patients with mild to moderate coronary artery disease and mild angina. Limited soft tissue discrimination due to inherently low contrast agent accumulation in atherosclerotic lesions has been one of the chief shortcomings of the field. Efforts to improve CT imaging have started with scanner enhancements to reduce artifacts, noise, and decrease radiation doses. Further, coupling CT angiography with calcium subtraction methods has been shown to improve image quality [51] . Another limitation of this technique is its intrinsic spatial resolution. Lesions can be imaged but little information can be gleaned to accurately describe plaque morphology specifically fibrous cap size. Effective analysis of plaque morphology can be used to predict and isolate vulnerable plaques (before rupture). As such, efforts to address these limitations have focused on the developing of contrast agents with higher X-ray attenuation. Metallic nanoparticles in particular can play a beneficial role.
Gold particles have been exploited in this setting for their high X-ray contrast and because the can be readily functionalized. Gold particles coated with HDLs have been used to mediate particle targeting to atherosclerotic plaques specifically, enabling plaque detection and also macrophage recruitment [159, 160] . Crystalline iodinated particles, while less sensitive than gold particles, have also been used for plaque targeting and analysis of macrophage entry [160] . Notably, these studies have focused on targeting plaques to identify macrophage burden and calcification in vulnerable plaques. For the purposes of imaging plaque-associated endothelium for diagnostic and therapeutic monitoring purposes, further advances must focus on improving CT spatial resolution, which must be high in order to achieve detailed vascular information.
Particles for MRI
Compared to other imaging modalities, MRI provides high soft tissue contrast and good spatial resolution [161] . There is a substantial amount of work that has been done in the development of targeted nanomaterials for imaging of the diseased endothelium in both cancer and cardiovascular disease. For cancer, both T1 and T2 agents have been developed. Specifically, in the case of T1 sensitivity, the paramagnetic properties of gadolinium (Gd) have been exploited widely. For example, Gd has been attached to small-molecule peptides and lipidbased nanoparticles (i.e., liposomes and lipid-based emulsions) for imaging of angiogenesis and tumor vasculature-associated matrix [159, 160] . Vascular targets include ICAM-1 [164] , VCAM-1 [145] , CD105 [165] , α v β 3 integrins [163] [164] [165] , fibrin-fibronectin [125] , and even multiple targets on the same carrier [166, 167] . Nanoparticles are particularly advantageous here compared to small-molecule agents because of the increased multivalency they provide for Gd decoration, which in turn provides a significant improvement on relaxivity [171] [172] [173] . Along these lines, dendrimers are also highly multivalent and ultrasmall dendrimers (5-10 nm in size that drives renal clearance) have been used for Gd-based targeting/imaging of folate receptorexpressing tumors and associated vasculature [174] . Gd-based agents have, however, proved toxic when clearance is impaired as in the case of patients with compromised renal function. As such, there are efforts to develop targeted MR agents with alternate nuclei, chiefly manganese, cobalt, and nickel [175] . In efforts to achieve minimal background signal, fluorine- [173, 174] and silica-based MR probes [175, 176] are being developed and have shown dramatic improvements in sensitivity, resolution, and quantitation.
Similarly, in developing T2-based particles, much effort has focused on the development of superparamagnetic iron oxide (SPIO) nanoparticles chiefly because they have high T2* sensitivity and detection thresholds in the micromolar range and allow for easy functionalization with a variety of targeting ligands [180] . Optimal MR imaging with SPIO particles depends on their magnetic properties, which, as studies have shown, depend on particle size and shape [181, 182] . SPIO particles functionalized with integrin targets [183] and VEGFR [184] have been used for molecular MR imaging of the tumor-associated endothelium. By further engineering of SPIO particles to form a chain, recent studies have shown targeting to tumor vascular integrins resulted in increased detection of breast tumor metastasis using MRI [85] . Given that their chainlike structure display geometrically enhanced multivalent targeting, these studies have shown that nanochains appear to attach to vascular targets with greater efficiency compared to their spherical counterparts. Targeting nanochains to α v β 3 integrins upregulated in metastatic foci and the associated vasculature resulted in significant retention compared to spheres even in micrometastases (b1 mm in size) that are, as yet, clinically undetectable [86] [87] [88] [89] .
Alternatively to methods that exploit T1 and T2 contrast, liposomebased chemical exchange saturation transfer (lipo-CEST) MR particles have also been developed [182, 183] . Here, using specific radio frequencies to discern proton signals from various molecules, CEST smallmolecule agents encapsulated in liposomes can help to increase contrast and reduce background by several orders of magnitude [187] . Lipo-CEST particles targeted to upregulated α ν β 3 integrins were Reproduced with permission from reference [61] .
shown to home with high efficiency to angiogenic vessels of brain tumors [188] .
MR imaging does not require radioisotopes or radiation, making it a more viable and safe modality with vulnerable patients. However, atherosclerosis imaging can be difficult using MR due to its long acquisition times and often sub-par signal-to-noise ratios primarily caused by motion artifacts; this behavior is typically exhibited in the coronary artery making it one of the most challenging arteries to image. Efforts to improve motion artifacts have included black-blood MR, increased magnetic fields, use of contrast agents, and other motion correcting/ compensating tools [189] . In order to acquire improved MR contrastto-noise ratio, research has focused on diseased endothelial vascular targeting and associated plaque accumulation contrast enhancers, which include liposomal Gd [190] , SPIO nanoparticles [146, 148, 188] , monocrystalline magnetic nanoparticles [145] , and Gd lipid-based emulsions [189, 47, 190] . Many of these techniques have overlap vascular targeting for cancer applications with uses in diagnostics and therapy.
VCAM-1 targeting has been of great interest in the field. For example, in lieu of antibody-mediated targeting, phage-display selection methods were used to identify several VCAM-1 peptide sequences that were amenable for rapid internalization upon contact with endothelial target cells. Further selection criteria included similarity to surface sequences on circulating hematopoetic cells and ability to attach to a fluorescence probe. Attachment of the resulting peptides to monocrystalline iron oxide nanoparticles showed that, in marked contrast to antibodymediated targeting, there was a significant increase in signal-to-noise ratio at target sites and subsequent endothelial cell uptake and longlasting accumulation. Optical imaging of the attached fluorescence probe was used to corroborate these MR findings (Fig. 7) [145] . Other multimodal particles have been used for spatial monitoring of VCAM-1 expression in lumen of diseased vessels [194] . Ultra-small SPIONs have also been used to target both VCAM-1 and P03011 [25] . Specifically in the case of P03011-targeted SPIONS, a high magnetic field was used to detect plaque accumulation with increased spatial resolution. However, while possible in preclinical studies, increasing the magnetic field as in this study is an engineering disadvantage when translating this technology for clinical use. Iron oxide microparticles have also been developed for MR imaging of plaques and associated vasculature. Specifically, dual-targeted microparticles decorated with both VCAM-1 and P-selectin antibodies showed a significant targeting advantage compared to particles targeted with individual ligands [195] .
Integrins, primarily α v β 3 integrins, are another targeting ligand family widely used for plaque and plaque-associated vasculature targeting. Atherosclerosis is known to promote angiogenesis, which aids in the further development of plaque size and later plaque rupture. In particular, α v β 3 integrins are known to mediate this angiogenesis. Monitoring the effects of angiogenesis via α v β 3 integrin imaging can also lead to detection of vulnerable plaques [189, 47, 190] . Initial MR imaging studies of angiogenesis in atherosclerosis involved the use of Gd-loaded lipidbased emulsion particles targeted to α v β 3 integrins [192] . Further, Gdloaded HDL particles [196] and SPIONs targeted to macrophages and apoptotic cells [146, 188] within the plaque lesion were also used for MR imaging of these sites.
Particles for ultrasound
US imaging is a low cost modality with the added advantages of high contrast and spatial resolution. Because many US agents have short halflives, US imaging is particularly suited to targeted vascular imaging since particles dock at their sites often within the first several hours of injection. Notably, significant focus has been placed on the development of submicron-and micron-sized carriers for the purposes of US imaging. In the case of cancer, over-expressed vascular VEGFR-2 [35, 194] and α v β 3 integrins [195] [196] [197] [198] [199] have been targets of choice for bubbles using both peptides and antibodies as targeting moieties. In particular, bubbles targeting VEGFR-2 have been used to monitor this receptor expression during treatment inhibiting angiogenesis [35, 195] . Further, micro-bubbles functionalized with both VEGFR-2 and α v β 3 targets have also shown significantly higher homing potential compared to bubbles with only one targeting species [203] .
Contrast-enhanced US is of increasing interest in atherosclerosis imaging due to low cost, widespread availability, and short imaging time. Bubbles are gas-filled lipid bilayers that undergo volumetric oscillations, size shrinkage and expansion, under an acoustic field, promoting significant contrast-enhancement in US. VCAM-1-targeted microbubbles have been used to measure vascular inflammation in lesion sites [201, 202] . Quantification of the expression levels of VCAM-1 at different stages of atherosclerosis can lead to valuable information that could enable classification of disease stage and associated biomarker expression. With the use of low frequency and high amplitude ultrasound waves, bubbles can be destroyed resulting in blank ultrasound images. Consequentially, this method can promote the use of multiple sequential vascular-targeted bubble formulations with varying targets. This analysis, in turn, could result in the detailed quantification of the expression levels of biomarkers as disease progresses. Echogenic immunoliposomes have been used based on this technique in efforts to develop an understanding of vascular receptor expression levels in atherosclerosis [203, 204] .
Particles for multimodal imaging
In the recent past, nanoparticle imaging agents have been developed for multimodal imaging. For instance, optical imaging and PET can be complementary to each other. A multimodal targeted nanoparticle can enable the use of PET for diagnostic purposes (e.g., surgery planning) and the use of optical imaging during therapeutic interventions (i.e., surgery). Along those lines, an MR-detectable and fluorescent liposome was developed for MR imaging and fluorescence microscopy [166] . By targeting α v β 3 integrins, multimodal molecular imaging facilitated detection of activated endothelium and angiogenic blood vessels. A different application of multimodal molecular imaging is the development of a 99m Tc-Gd nanoparticle targeting α v β 3 integrins for molecular imaging of angiogenesis. The MR modality facilitates molecular imaging of angiogenesis with reasonable anatomical details, while the high sensitivity (but lower resolution) SPECT achieved detection of small lesions that were missed by MRI [209] .
In the case of atherosclerosis, PET/CT [207, 166] , SPECT/CT [191] , and CT/MRI/optical imaging [160] has been used to target macrophages at plaque sites. For the purposes of nanoparticle vascular targeting, VCAM-1-targeted particles conjugated to NIR probes have been used for dual MRI/optical imaging [145, 147, 191] . Similarly, ICAM-1 has also been used for multimodal particle targeting and imaging [190] .
Considerations for clinical translation
In the previous sections, we reviewed a variety of nanoparticles designed for the most popular modalities used for molecular imaging: nuclear imaging, optical imaging, CT, MRI, and ultrasound. Table 1 illustrates that these imaging modalities present significantly different spatial resolution, penetration depth, contrast sensitivity and cost, which should be carefully considered to identify the most appropriate modality for a specific application.
While the predominant drive in academic research is and will continue to be scientific discovery and novelty, the successful development of a molecular imaging agent should carefully consider its bench-tobedside translation leading to improved patient outcomes. In this context, the early-stage preclinical development of imaging agents needs to be mindful of aspects related to clinical adaptation and regulatory approval that extend well beyond successful imaging of overexpressed biomarkers in animal models. Such aspects include: 1) a well-defined unmet clinical need that the imaging agent addresses, 2) preclinical toxicity and safety, 3) identification of the primary clinical indication. Additionally, due to the complexity of manufacturing and controls (CMC) for clinical-grade nanoparticles, an early-stage analysis of the overall cost of product development can provide justification in terms of added benefits in terms of overall clinical impact. Further, contrary to conventional low molecular weight compounds, nanoparticle imaging agents present new safety considerations due to different in vivo pharmacokinetics and distribution. Additionally, the safety requirement for imaging agents is very high, since the target populations can be healthy subjects or low-risk cancer patients. This consideration makes evaluation of the benefit-to-risk ratio even more important.
Taking under consideration the manufacturing and safety requirements, radionuclide-based molecular imaging often provides the highest clinical relevance for widespread use in the clinic. While the resolution of either SPECT or PET (N1 mm) is not very high, radionuclide imaging provides high sensitivity, deep-tissue penetration, and quantitative nature. Clearly, the major advantage of SPECT and PET over other modalities (e.g., CT, MRI) is their extraordinary sensitivity (down to the picomolar level). Thus, in addition to the diagnostic metrics of sensitivity and specificity, toxicity concerns of nanoparticle radiotracers are often alleviated, since tracer amounts are needed for radionuclidebased molecular imaging.
In summary, demonstration of clinical effectiveness strongly depends on the selection of the appropriate nanoparticle, imaging modality and clinical indication, which can then lead to substantial improvement in patient management. For instance, identification of the appropriate targets for 'quantitative' molecular imaging of plaque vulnerability can provide valuable guidance to the clinician for managing individual patients and preventing plague rupture. As discussed in previous sections, representative targets of atherosclerotic features related to plaque vulnerability include neovascularization and plaque inflammation. Furthermore, the combination of vascular targeting and nanoparticle imaging agents can lead to significant improvements in management of cancer patients. The concept of occult disease or "micrometastasis" emphasizes that when cancer patients have distant micrometastatic disease at the time of diagnosis, their risk for later development of overt metastatic disease is very high. Unfortunately, Since the purpose of systemic therapy is typically to eradicate distant micrometastases, it is essential to evaluate the risk of an individual patient of harboring clinically silent micrometastatic disease. It is equally important to be able to select the optimal adjuvant or neoadjuvant therapy for an individual patient based on accurate diagnostic testing. While it is standard practice to administer systemic therapy to all patients with node-positive disease, it is clear that non-invasive and quantitative detection of lymph node metastasis or micrometastatic disease in distant organs may warrant more aggressive therapeutic approaches. In more advanced disease scenarios, nanoparticle-based molecular imaging can be developed for guiding treatment decisions around locoregional versus systemic treatment.
Conclusions
In conclusion, this review highlights the enormous potential of nanoparticles for molecular imaging applications due to multivalency, binding avidity and overall specificity and sensitivity of nanoparticles. It is further apparent that the natural synergy with vascular targeting can provide new avenues for diagnosis and prognosis of disease with quantitative precision. In addition to the obvious applications of targeting the molecular make-up of vascular diseases (e.g., atherosclerosis), manifestation of other diseases, such cancer metastasis, initially occur on the endothelium providing opportunities for early detection and characterization of disease that are currently undetectable by today's imaging techniques. Furthermore, most diseases continuously alter and remodel the endothelium providing a wide range of targets for molecular imaging, which will expand the diagnostic and prognostic value of imaging beyond anatomical and functional information. Thus, the prospect of added value in terms of improved patient management and outcomes justifies the extra complexity of nanoparticles' fabrication, cost and regulatory procedures.
While the promise of targeted nanoparticles and molecular imaging is unquestionable, the field has suffered from poorly designed preclinical studies that lack clear clinical relevance or a well-defined endpoint. However, the field is maturing and preclinical development of nanotechnologies is increasingly becoming mindful of the clinical deployment even at the early stages of research, which can lead to molecular imaging that provides valuable assistance to clinicians and informs their decision-making process.
